Abstract

AIM
The aim of the study was to determine the intraocular pressure (IOP) changes with high-dose intravenous methylprednisolone (HIVMP) treatment given for the treatment of acute relapses in relapsing multiple sclerosis (MS).
METHODS
Forty patients with clinically definite MS admitted for a new demyelinating event were included in the study. All patients were treated with HIVMP (1 g) once daily for 5 consecutive days. IOPs of 40 patients were recorded before treatment, during the course of systemic methylprednisolone administration and at the end of each month for 3 successive months, four times a day. The average IOP of each day was statistically compared to the pretreatment value.
RESULTS
The initial IOP was 13.5 ± 2.4 mm Hg before steroid administration. The IOP values tended to rise significantly during intravenous corticosteroid administration and in the first month of follow-up (p < 0.05). However, the increase remained within normal ranges and IOP values never exceeded 20 mm Hg during the follow-ups.
CONCLUSION
Our study demonstrated that MS patients treated with HIVMP have increased IOP which does not lead to conditions at risk for developing glaucoma.

Links

Publisher Full Text

Authors

Acar M, Gedizlioglu M, Koskderelioglu A, Ozturk F, Kilinc S, Talay N

Institution

Department of Ophthalmology, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey.

Source

European neurology 68:1 2012 pg 20-2

MeSH

Adult
Anti-Inflammatory Agents
Female
Humans
Infusions, Intravenous
Intraocular Pressure
Male
Methylprednisolone
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
Young Adult

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

22677889